Please assess the completion status of the following clinical trial:

Trial Title: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of UC for at least 3 months prior to baseline.~* Confirmed diagnosis of moderately or severely active UC, as assessed by the modified Mayo score (MMS).~* Demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic therapy for UC.~* If female, must meet the contraception requirements.~Exclusion Criteria:~* Participants with a current diagnosis of Crohn's disease or inflammatory bowel disease-unclassified (indeterminate colitis).~* Participants with a previous colectomy.~* Participants with current evidence of toxic megacolon.~* Prior exposure to anti-IL12p40 antibodies (e.g. ustekinumab) or anti-IL-23p19 antibodies (e.g. risankizumab, brazikumab, guselkumab or tildrakizumab).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Intravenous (IV) Every 4 Weeks (Q4W) (Type: PLACEBO_COMPARATOR): Placebo given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
- 300 Milligram (mg) Mirikizumab IV Q4W (Type: EXPERIMENTAL): 300 mg mirikizumab given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
- Placebo IV Q4W Maximum Extended Enrollment (ME2) (Type: PLACEBO_COMPARATOR): Placebo given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
- 300 mg Mirikizumab IV Q4W ME2 (Type: EXPERIMENTAL): 300 mg mirikizumab given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).